Mignot’s goal in his study was to define the hypocretin deficiency syndrome and determine whether or not measurement of the number of hypocretin cells can be used to diagnose narcolepsy. They determined the amount of hypocretin cells in narcoleptic subjects and people with normal levels of hypocretin by the Multiple Sleep Latency Test and signal detection analysis.
Their results show that people with narcolepsy as well as cataplexy had an HLA frequency of about 93% while narcoleptics without cataplexy had a frequency of 56%. They also found that hypocretin levels above 200 pg/mL was normal, while hypocretin levels of 110 pg/mL signified narcolepsy.
Because of these results, Mignot determined that measureing CSF hypocretin-1 is a valid test to determine whether a person has narcolepsy. Measurements would also work better with narcoleptics who experience cataplexy.
For further details of the study, click the following link:
0 comments:
Post a Comment